The TGA has approved a dual immunotherapy regimen combined with limited chemotherapy for the frontline treatment of some advanced non-small cell lung cancers (NSCLC). The combination of nivolumab (Opdivo), a PD-1 inhibitor, plus ipilimumab (Yervoy), a CTLA-4 inhibitor, with two cycles of platinum-doublet chemotherapy received TGA registration last week following US FDA approval in May. ...
Dual immunotherapy approved for NSCLC
By Sunalie Silva
30 Jul 2020